Arvinas Inc
Arvinas Inc (ARVN) is a clinical-stage biotechnology company developing targeted protein degraders — molecules designed to remove disease-causing proteins rather than merely inhibit them. Its pipeline centres on programmes for hormone-driven cancers (oestrogen and androgen receptor degraders) and earlier-stage assets exploring other disease areas. With a market capitalisation of about $709.21m, Arvinas is a small-cap, research-led firm: its value is closely tied to clinical trial results, regulatory decisions and potential licensing or partnership deals. The company has secured industry collaborations that can provide funding and development expertise, but commercial success is not guaranteed. Investing in Arvinas offers exposure to a differentiated scientific platform with upside if key trials succeed, while also carrying typical biotech risks such as trial setbacks, lengthy development timelines and potential equity dilution from fundraising. This summary is educational general information only and not personalised investment advice; investors should assess suitability and risk tolerance before acting.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Arvinas' stock with a target price of $12.82, indicating slight growth potential.
Financial Health
Arvinas Inc is generating solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ARVN
Next-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially move the share price; outcomes are binary and timings uncertain, so expect volatility.
Platform Potential
Targeted protein degradation could broaden treatable diseases and create new medicines, though the science is still early and success is not assured.
Partner Collaborations
Industry partnerships can provide funding and development expertise, helping de‑risk programmes, but commercialisation and market uptake remain to be proven.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
